These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1012 related articles for article (PubMed ID: 33570575)

  • 1. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
    Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
    Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
    Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
    Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
    Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Santoni M; Tudini M; Rijavec E; Filetti M; Catino A; Pizzutilo P; Sala L; Citarella F; Marco R; Torniai M; Cantini L; Targato G; Sforza V; Nigro O; Ferrara MG; D'Argento E; Buti S; Bordi P; Antonuzzo L; Scodes S; Landi L; Guaitoli G; Baldessari C; Della Gravara L; Dal Bello MG; Belderbos RA; Bironzo P; Carnio S; Ricciardi S; Grieco A; De Toma A; Proto C; Friedlaender A; Cantale O; Ricciuti B; Addeo A; Metro G; Ficorella C; Porzio G
    Cancer Immunol Immunother; 2020 Nov; 69(11):2209-2221. PubMed ID: 32474768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
    Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T
    Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
    Alessi JV; Ricciuti B; Jiménez-Aguilar E; Hong F; Wei Z; Nishino M; Plodkowski AJ; Sawan P; Luo J; Rizvi H; Carter BW; Heymach JV; Altan M; Hellmann M; Awad M
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
    Tamiya M; Tamiya A; Hosoya K; Taniguchi Y; Yokoyama T; Fukuda Y; Hirano K; Matsumoto H; Kominami R; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Kinoshita Y; Hara S; Kumagai T; Fujimoto D
    Invest New Drugs; 2019 Dec; 37(6):1266-1273. PubMed ID: 31392549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
    Mountzios G; de Toma A; Economopoulou P; Friedlaender A; Banini M; Lo Russo G; Baxevanos P; Roila F; Banna GL; Christopoulou A; Jimenez B; Collazo-Lorduy A; Linardou H; Calles A; Galetta D; Addeo A; Camerini A; Pizzutilo P; Kosmidis P; Garassino MC; Proto C; Signorelli D; Metro G
    Clin Lung Cancer; 2021 Mar; 22(2):e180-e192. PubMed ID: 33162330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
    Friedlaender A; Metro G; Signorelli D; Gili A; Economopoulou P; Roila F; Banna G; De Toma A; Camerini A; Christopoulou A; Lo Russo G; Banini M; Galetta D; Jimenez B; Collazo-Lorduy A; Calles A; Baxevanos P; Linardou H; Kosmidis P; Mountzios G; Garassino MC; Addeo A
    Acta Oncol; 2020 Sep; 59(9):1058-1063. PubMed ID: 32762415
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
    Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
    Amrane K; Geier M; Corre R; Léna H; Léveiller G; Gadby F; Lamy R; Bizec JL; Goarant E; Robinet G; Gouva S; Quere G; Abgral R; Schick U; Bernier C; Chouaid C; Descourt R
    Cancer Med; 2020 Apr; 9(7):2309-2316. PubMed ID: 32022459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line pembrolizumab efficacy in patients with advanced non-small cell lung cancer: A Bi-center retrospective, real-life experience study.
    Diker O; Olgun P
    J BUON; 2021; 26(3):844-852. PubMed ID: 34268944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
    Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
    Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
    Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
    Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
    Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
    Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
    Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
    Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
    JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
    Aarnink A; Fumet JD; Favier L; Truntzer C; Ghiringhelli F
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2699-2707. PubMed ID: 32474752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.